Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study
18 nov. 2024 08h45 HE
|
Dogwood Therapeutics, Inc.
- IMC-2 treatment, dosed as valacyclovir 750 mg + celecoxib 200 mg twice daily, demonstrated clinically meaningful reduction in Long-COVID related fatigue and sleep disturbance as compared to placebo...
Dogwood Therapeutics Announces Third Quarter 2024 Financial Results
07 nov. 2024 07h05 HE
|
Dogwood Therapeutics, Inc.
- Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”) formed in October by combination of Virios Therapeutics, Inc. and Pharmagesic (Holdings) Inc., 100% parent company of Wex Pharmaceuticals, Inc. (the...
Endonovo Launches Telehealth Initiative
13 déc. 2022 09h11 HE
|
Endonovo Therapeutics, Inc.
Expands Patient Education, Access to Non-Opioid Options for Pain Management Los Angeles, CA, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced the...
Sorrento Therapeutics Completes Enrollment of Phase 2 Clinical Trial of Resiniferatoxin (RTX) for Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients
26 sept. 2022 09h00 HE
|
Sorrento Therapeutics, Inc.
Phase 2 trial of RTX for OAK pain completed enrollment with last patient (n=120) dosedNo limiting toxicities have been encountered during the trial to date. Patients are now being monitored for...
FDA Clearance of an Expanded Indication for the SPRINT® PNS System Now Enables Treatment in Areas of the Head, Neck, and Torso
19 oct. 2021 12h22 HE
|
SPR Therapeutics, Inc.
CLEVELAND, Ohio, Oct. 19, 2021 (GLOBE NEWSWIRE) -- SPR Therapeutics® has obtained clearance from the U.S. Food and Drug Administration (FDA) of a broader indication for use for its SPRINT Peripheral...
FDA Clears Sorrento Phase 2 Trial Of Non-Opioid Product Candidate Resiniferatoxin (RTX) For Treatment of the Knee Pain in Osteoarthritis (OA) Patients
06 juil. 2021 14h34 HE
|
Sorrento Therapeutics, Inc.
Phase 2 trial of RTX for OA pain to proceed following FDA clearance.Phase 1b data demonstrated RTX safety for a single intra-articular administration without dose limiting toxicity (DLT) at any doses...
Multi-center Study Demonstrates Significant Reductions in Postoperative Pain and Opioid Use Following Peripheral Nerve Stimulation Treatment
26 avr. 2021 09h41 HE
|
SPR Therapeutics, Inc.
CLEVELAND, April 26, 2021 (GLOBE NEWSWIRE) -- Results of a multicenter trial recently published in Anesthesiology, the official peer-reviewed journal of the American Society of Anesthesiologists,...
Sorrento Therapeutics and Scilex Holding, a Majority Owned Subsidiary, Have Entered Into an Exclusive Licensing Term Sheet With Aardvark Therapeutics to Acquire Its ARD-301 For the Treatment of Chronic Pain, Fibromyalgia, and Chronic Long Haul Covid Syndrome
01 mars 2021 12h21 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics (NASDAQ: SRNE, “Sorrento”) and Scilex Holdings Company (“Scilex”), a majority owned subsidiary of Sorrento, have entered...
Neuropathix, Inc. CEO Recaps 2020 Advances and Potential Ahead
25 janv. 2021 09h00 HE
|
Neuropathix, Inc.
DOYLESTOWN, Pa., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Neuropathix, Inc. (“Neuropathix” or the “Company”) (OTCQB: NPTX), a socially responsible pain management life sciences company, announced today...
Melt Pharmaceuticals Enters the Clinical Stage of MELT-100 Development
29 juil. 2020 07h00 HE
|
Melt Pharmaceuticals
FDA has accepted MELT-100 IND; Phase 1 study enrollment to start immediately BOSTON, July 29, 2020 (GLOBE NEWSWIRE) -- Melt Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing...